Inj fosnetupitant, palonoset
Products billed under this code include Akynzeo.
Payment limit per 0.25 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Akynzeo.
Payment limit per 0.25 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Akynzeo | Helsinn Therapeutics (U.S.), Inc. | 69639-0105-01 | 1 | $479.902 |
| Akynzeo | Helsinn Therapeutics (U.S.), Inc. | 69639-0106-01 | 1 | $479.902 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $479.902 | −$23.946 | 0.25 MG | Inj fosnetupitant, palonoset | v1, posted September 17, 2026 |
| 3Q26 | $503.848 | −$20.329 | 0.25 MG | Inj fosnetupitant, palonoset | v1, posted September 15, 2026 |
| 2Q26 | $524.177 | −$22.755 | 0.25 MG | Inj fosnetupitant, palonoset | v1, posted September 15, 2026 |
| 1Q26 | $546.932 | −$28.571 | 0.25 MG | Inj fosnetupitant, palonoset | v1, posted September 15, 2026 |
| 4Q25 | $575.503 | −$30.851 | 0.25 MG | Inj fosnetupitant, palonoset | v1, posted September 8, 2026 |
| 3Q25 | $606.354 | −$26.521 | 0.25 MG | Inj fosnetupitant, palonoset | v1, posted March 10, 2026 |
| 2Q25 | $632.875 | −$25.225 | 0.25 MG | Inj fosnetupitant, palonoset | v1, posted March 10, 2026 |
| 1Q25 | $658.10 | −$21.41 | 0.25 MG | Inj fosnetupitant, palonoset | v1, posted December 19, 2025 |
| 4Q24 | $679.51 | −$7.635 | 0.25 MG | Inj fosnetupitant, palonoset | v1, posted June 11, 2025 |
| 3Q24 | $687.145 | −$21.20 | 0.25 MG | Inj fosnetupitant, palonoset | v1, posted June 11, 2025 |
| 2Q24 | $708.345 | +$14.167 | 0.25 MG | Inj fosnetupitant, palonoset | v1, posted March 11, 2025 |
| 1Q24 | $694.178 | +$165.799 | 0.25 MG | Inj fosnetupitant, palonoset | v1, posted December 19, 2024 |
| 4Q23 | $528.379 | +$156.38 | 0.25 MG | Inj fosnetupitant, palonoset | v1, posted October 10, 2024 |
| 3Q23 | $371.999 | −$20.665 | 0.25 MG | Inj fosnetupitant, palonoset | v1, posted June 5, 2024 |
| 2Q23 | $392.664 | −$74.394 | 0.25 MG | Inj fosnetupitant, palonoset | v1, posted February 23, 2024 |
| 1Q23 | $467.058 | +$37.042 | 0.25 MG | Inj fosnetupitant, palonoset | v1, posted December 6, 2023 |
| 4Q22 | $430.016 | −$36.058 | 0.25 MG | Inj fosnetupitant, palonoset | v1, posted June 22, 2023 |
| 3Q22 | $466.074 | +$1.691 | 0.25 MG | Inj fosnetupitant, palonoset | v1, posted June 9, 2023 |
| 2Q22 | $464.383 | −$39.596 | 0.25 MG | Inj fosnetupitant, palonoset | v1, posted December 14, 2022 |
| 1Q22 | $503.979 | −$67.242 | 0.25 MG | Inj fosnetupitant, palonoset | v1, posted June 8, 2022 |
| 4Q21 | $571.221 | −$22.979 | 0.25 MG | Inj fosnetupitant, palonoset | v1, posted June 2, 2022 |
| 3Q21 | $594.20 | −$47.047 | 0.25 MG | Inj fosnetupitant, palonoset | v1, posted June 2, 2022 |
| 2Q21 | $641.247 | −$54.311 | 0.25 MG | Inj fosnetupitant, palonoset | v1, posted March 1, 2022 |
| 1Q21 | $695.558 | – | 0.25 MG | Inj fosnetupitant, palonoset | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.